Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan in ALS
NCT03505021Phase 3Completed
- Sponsor
- Orion Corporation
- Start
- Jun 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Levosimendan with Placebo (2 arms). Primary endpoint: Supine Slow Vital Capacity at 12 weeks. Started Jun 2018; status: completed.
02
Drugs
levosimendan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03505021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505021.